| abstract |
Substd. azole derivs. of formula (I) and their physiologically acceptable salts are new. In (I) X, Y and Z are each N or CR2 R1 is 2-10C alkyl, 3-10C alkenyl, 3-10C alkynyl, -(CH2)mB(CH2nR4 (these 4 gps. opt. monosubstd. with CO2R3 and opt. have 1-all H atoms replaced by F), OR3, 3-8C cycloalkyl, 5-10C cycloalkylalkynyl, or benzyl (opt. mono or disubstd. on the Ph ring with halogen, 1-4C alkoxy and/or NO2), R2 = H, halogen, CvF2v+1, SF5, pentafluoro phenyl CN, phenyl, -(CH2)nF, -(CH2)nONO2, -CH2N3, -(CH2)nNO2, phthalimido (CH2)n-, R3 = H, 1-8C alkyl (in which 1 to all H are replaced by F), 3-8C cycloalkyl, Ph or benzyl, R4 = H, 1-6C alkyl, 3-8C cycloalkyl, 2-4C alkenyl, or 2-4C alkynyl, A = a mono or bicyclic unsatd. or partially hydrogenated heterocycle gp. with 5-10 ring atom of which up to 9 are C, and opt. substd. with up to 3 opt. different R14 gps. or -(CH2)n-1-(CHR6CH2)0-1, R14 where R14 = halogen, oxo, nitroso, NO2, amino, CN, OH, 1-6C alkyl, 1-4C alkanoyl, 1-4C alkanoyloxy. B = O, NR7 or S, W = O or S, L = 1-3C alkanediyl, R26 and R27 are each H, halogen, NO2, 1-4C alkyl or 1-2C alkoxy, n = 1-5, o = 1-10, q = 0-1.n[DE4023215A1] |